Aspirin resistance: More than just a laboratory curiosity

Journal of the American College of Cardiology

Volumn 43, Issue 6, 2004, Pages 1127-1129

  Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG RESISTANCE; EDITORIAL; EVALUATION; HUMAN; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STANDARDIZATION;

ASPIRIN; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 1542498752     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.01.022     Document Type: Editorial

References (28)

1. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2:2003;15-28.
2. Califf R.M., DeLong E.R., Ostbye T., et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 89:2002;653-661.
3. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 88:2001;230-235.
4. Bhatt D.L., Topol E.J. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am. 84:2000;163-179.
5. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 105:2002;1650-1655.
6. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 41:2003;961-965.
7. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.
8. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324:2002;71-86.
9. Peters R.J., Mehta S.R., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 108:2003;1682-1687.
10. Topol E.J., Easton D., Harrington R.A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 108:2003;399-406.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339.
12. Bhatt D.L., Chew D.P., Hirsch A.T., Ringleb P.A., Hacke W., Topol E.J. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 103:2001;363-368.
13. Macchi L., Christiaens L., Brabant S., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 107:2002;45-49.
14. Serebruany V.L., Malinin A.I., Jerome S.D., et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J. 146:2003;713-720.
15. Csiszar A., Stef G., Pacher P., Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids. 66:2002;557-558.
16. Szczeklik A., Musial J., Undas A., et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol. 33:1999;1286-1293.
17. Christiaens L., Macchi L., Herpin D., et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res. 108:2002;115-119.
18. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
19. Chew D.P., Bhatt D.L., Robbins M.A., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 88:2001;672-674.
20. Bhatt D.L., Topol E.J. Need to test the arterial inflammation hypothesis. Circulation. 106:2002;136-140.
21. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 345:2001;1809-1817.
22. Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 353:1999;900.
23. Zimmermann N., Wenk A., Kim U., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 108:2003;542-547.
24. Macchi L., Christiaens L., Brabant S., et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ib-alpha) polymorphisms. J Am Coll Cardiol. 42:2003;1115-1119.
25. Undas A., Brummel K., Musial J., Mann K.G., Szczeklik A. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 104:2001;2666-2672.
26. Pontiggia L., Lassila R., Pederiva S., Schmid H.R., Burger M., Beer J.H. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GP Ia and GP IIIa. Arterioscler Thromb Vasc Biol. 22:2002;2093-2098.
27. Quinn M.J., Topol E.J. Common variations in platelet glycoproteins pharmacogenomic implications. Pharmacogenomics. 2:2001;341-352.
28. Halushka M.K., Walker L.P., Halushka P.V. Genetic variation in cyclooxygenase 1 effects on response to aspirin. Clin Pharmacol Ther. 73:2003;122-130.